virus-like particle vaccines Dotaz Zobrazit nápovědu
SARS-CoV-2 claimed numerous lives and put nations on high alert. The lack of antiviral medications and the small number of approved vaccines, as well as the recurrence of adverse effects, necessitates the development of novel treatment ways to combat COVID-19. In this context, using databases such as PubMed, Google Scholar, and Science Direct, we gathered information about nanotechnology's involvement in the prevention, diagnosis and virus-like particle vaccine development. This review revealed that various nanomaterials like gold, polymeric, graphene and poly amino ester with carboxyl group coated magnetic nanoparticles have been explored for the fast detection of SARS-CoV-2. Personal protective equipment fabricated with nanoparticles, such as gloves, masks, clothes, surfactants, and Ag, TiO2 based disinfectants played an essential role in halting COVID-19 transmission. Nanoparticles are used not only in vaccine delivery, such as lipid nanoparticles mediated transport of mRNA-based Pfizer and Moderna vaccines, but also in the development of vaccine as the virus-like particles elicit an immune response. There are now 18 virus-like particle vaccines in pre-clinical development, with one of them, developed by Novavax, reported being in phase 3 trials. Due to the probability of upcoming COVID-19 waves, and the rise of new diseases, the future relevance of virus-like particles is imperative. Furthermore, psychosocial variables linked to vaccine reluctance constitute a critical problem that must be addressed immediately to avert pandemic.
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Antimicrobial peptides are currently considered as promising antiviral compounds. Current assays to evaluate the effectivity of peptides against enveloped viruses based on liposomes or hemolysis are encumbered by the artificial nature of liposomes or distinctive membrane composition of used erythrocytes. We propose a novel assay system based on enzymatic Ebola virus-like particles containing sensitive luciferase reporter. The assay was validated with several cationic and anionic peptides and compared with lentivirus inactivation and hemolytic assays. The assay is sensitive and easy to perform in standard biosafety level laboratory with potential for high-throughput screens. The use of virus-like particles in the assay provides a system as closely related to the native viruses as possible eliminating some issues associated with other more artificial set ups. We have identified CAM-W (KWKLWKKIEKWGQGIGAVLKWLTTWL) as a peptide with the greatest antiviral activity against infectious lentiviral vectors and filoviral virus-like particles.
- MeSH
- anionty MeSH
- antivirové látky farmakologie MeSH
- hemoragická horečka Ebola prevence a kontrola virologie MeSH
- kationické antimikrobiální peptidy farmakologie MeSH
- Lentivirus účinky léků genetika MeSH
- lidé MeSH
- liposomy chemie MeSH
- peptidy farmakologie MeSH
- virus Ebola účinky léků patogenita MeSH
- VLP vakcíny MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Tick-borne encephalitis virus (TBEV) is a tick-borne flavivirus that induces severe central nervous system disorders. It has recently raised concerns due to an expanding geographical range and increasing infection rates. Existing vaccines, though effective, face low coverage rates in numerous TBEV endemic regions. Our previous work demonstrated the immunogenicity and full protection afforded by a TBEV vaccine based on virus-like particles (VLPs) produced in Leishmania tarentolae cells in immunization studies in a mouse model. In the present study, we explored the impact of adjuvants (AddaS03TM, Alhydrogel®+MPLA) and administration routes (subcutaneous, intramuscular) on the immune response. Adjuvanted groups exhibited significantly enhanced antibody responses, higher avidity, and more balanced Th1/Th2 response. IFN-γ responses depended on the adjuvant type, while antibody levels were influenced by both adjuvant and administration routes. The combination of Leishmania-derived TBEV VLPs with Alhydrogel® and MPLA via intramuscular administration emerged as a highly promising prophylactic vaccine candidate, eliciting a robust, balanced immune response with substantial neutralization potential.
- MeSH
- adjuvancia imunologická * aplikace a dávkování MeSH
- adjuvantní vakcína aplikace a dávkování MeSH
- imunogenicita vakcíny MeSH
- injekce intramuskulární MeSH
- interferon gama imunologie MeSH
- klíšťová encefalitida * prevence a kontrola imunologie MeSH
- Leishmania * imunologie MeSH
- myši inbrední BALB C MeSH
- myši MeSH
- neutralizující protilátky krev imunologie MeSH
- protilátky virové * krev imunologie MeSH
- syntetické vakcíny * imunologie aplikace a dávkování MeSH
- Th1 buňky imunologie MeSH
- virové vakcíny * imunologie aplikace a dávkování MeSH
- viry klíšťové encefalitidy * imunologie MeSH
- VLP vakcíny * imunologie aplikace a dávkování MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- MeSH
- chiméra genetika imunologie MeSH
- cytotoxické T-lymfocyty fyziologie MeSH
- lidé MeSH
- nádory děložního čípku etiologie prevence a kontrola MeSH
- Papillomaviridae genetika imunologie MeSH
- preventivní lékařství MeSH
- rekombinace genetická MeSH
- virové vakcíny MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- přehledy MeSH
Většina karcinomů děložního hrdla vzniká v souvislosti s perzistentní infekcí vysoce rizikových kmenů lidských papilomavirů (HR HPV). Schopnosti papilomavirového L1-kapsidového proteinu tvořit neinfekční virus-like částice bylo využito k vývoji profylaktických vakcín, které jsou bezpečné, vysoce imunogenní a vykazují u plně vakcinovaných žen kompletní typově specifickou ochranu proti perzistentní infekci HR HPV a s ní asociovaných lézí.
Persistent high-risk human papillomavirus (HPV) infection is the cause of most of instances of cervical cancer. The ability of HPV - L1 capsid protein to form non-infectious virus-like particles was the basis for the development of prophylactic vaccines which are safe and highly immunogenic, and which provide complete type-specific protection against persistent HPV infection and associated lesions in fully vaccinated women.
Tick-borne encephalitis virus (TBEV) is a major cause of neurological infections in many regions of central, eastern and northern Europe and northern Asia. In approximately 15% of cases, TBEV infections lead to the development of severe encephalitis or meningitis. The main route of TBEV transmission is tick bites; however, ingestion of dairy products from infected animals (goats, cattle and sheep) is also a frequent cause of the disease. Therefore, vaccination of livestock in virus endemic regions could also contribute to the decrease in TBEV infection among humans. Although few vaccines against TBEV based on inactivated viruses are available for humans, due to high costs, vaccination is not mandatory in most of the affected countries. Moreover, there is still no vaccine for veterinary use. Here, we present a characterization and immunogenicity study of a new potential TBEV vaccine based on virus-like particles (VLPs) produced in Leishmania tarentolae cells. VLPs, which mimic native viral particles but do not contain genetic material, show good immunogenic potential. For the first time, we showed that the protozoan L. tarentolae expression system can be successfully used for the production of TBEV virus-like particles with highly efficient production. We confirmed that TBEV recombinant structural proteins (prM/M and E) from VLPs are highly recognized by neutralizing antibodies in in vitro analyses. Therefore, VLPs in combination with AddaVax adjuvant were used in immunization studies in a mouse model. VLPs proved to be highly immunogenic and induced the production of high levels of neutralizing antibodies. In a challenge experiment, immunization with VLPs provided full protection from lethal TBE in mice. Thus, we suggest that Leishmania-derived VLPs may be a good candidate for a safe alternative human vaccine with high efficiency of production. Moreover, this potential vaccine candidate may constitute a low-cost candidate for veterinary use.
- MeSH
- klíšťová encefalitida * prevence a kontrola MeSH
- Leishmania * MeSH
- lidé MeSH
- myši MeSH
- neutralizující protilátky MeSH
- ovce MeSH
- protilátky virové MeSH
- skot MeSH
- virové vakcíny * MeSH
- viry klíšťové encefalitidy * genetika MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- skot MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Vaccine strategies for the treatment of human papillomavirus-induced cervical cancer are based mainly on the human papillomavirus 16 E7 (HPV16 E7) oncoprotein. The immunogenicity of the E7 gene has been enhanced by its fusion to many different genes. Here, we linked a short sequence coding for the E7 peptide (aa 44-60) containing immunodominant epitopes for B and T cells to the 3' end of the gene coding for the whole coat protein (CP) of the poty-virus, potato virus A (PVA), and its deleted form (CPdel) with a short C-terminal deletion of 5 amino acids (LGVKG). CP-E7 and CPdel-E7 fusion proteins, just like CP alone, spontaneously assembled into virus-like particles in both procaryotic and eucaryotic cells. The CP-E7 and CPdel-E7 fusion genes induced slightly stronger E7-specific cytotoxic T-lymphocyte responses than the whole E7 gene, although they were still lower than those elicited by the previously constructed fusion gene, Sig/E7GGG/LAMP-1. The E7- and CP-specific antibody responses were not detected in mice vaccinated with CP-E7 and CPdel-E7 fusion genes. The CP-E7 and CPdel-E7 fusion genes protected mice against the development of tumors induced by TC-1 cells producing the E7 antigen and were also effective in the therapeutic setting, i.e. when the vaccination was performed after tumor cell administration. Their antitumor effect was comparable to those of the whole E7 gene and Sig/E7GGG/LAMP-1 fusion gene. There was no relevant difference between immune responses elicited by CP-E7 and CPdel-E7 DNA vaccination.
- MeSH
- biolistika MeSH
- buněčné linie MeSH
- buňky NIH 3T3 MeSH
- časové faktory MeSH
- cytotoxické T-lymfocyty cytologie MeSH
- DNA vakcíny MeSH
- ELISA MeSH
- financování organizované MeSH
- genetická terapie metody MeSH
- hmotnostní spektrometrie MeSH
- lidé MeSH
- molekulární sekvence - údaje MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- nádorové buněčné linie MeSH
- onkogenní proteiny virové chemie MeSH
- peptidy chemie MeSH
- plazmidy metabolismus MeSH
- Potyvirus genetika MeSH
- protinádorové látky farmakologie MeSH
- protinádorové vakcíny MeSH
- rekombinantní fúzní proteiny chemie MeSH
- RNA chemie MeSH
- sekvence aminokyselin MeSH
- sekvenční homologie aminokyselin MeSH
- spektrometrie hmotnostní - ionizace laserem za účasti matrice MeSH
- technika přenosu genů MeSH
- transmisní elektronová mikroskopie MeSH
- transplantace nádorů MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
Carcinoma of the cervix (CaCer) is the second most frequent malignancy in women on a global scale. Epidemiological studies carried out at the beginning of the second half of the 20th century showed that CaCer was of infectious nature and that its agent was transmitted by sexual intercourse. For some 15 years, herpes simplex virus type 2 (HSV2), the genital herpes virus, was suspected to be the etiological agent. This hypothesis was disproved just in the time when the first convincing evidence that the agents of the disease were human papillomaviruses (HPVs) was produced. Copious new findings obtained during the 1980's and 1990's unequivocally confirmed that HPVs were the causative agents. The most dangerous among the over 100 HPV types are types 16 and 18, which together account for over 70% of CaCer cases and very likely also for most of the other malignancies of the anogenital region and the oropharynx. Extensive research of the HPV biology and immunology enabled the development of vaccines based on the s.c. virus-like particles (VLP) prepared by genetic engineering. At present, there is one HPV vaccine on the market; it contains, besides types 16 and 18, also types 6 and 11, the causative agents of certain benign tumours of the genital area and of the larynx. A new vaccine, comprising types 16 and 18 only, the product of another firm, is to appear on the market soon. Both vaccines have already been tested in extensive clinical trials. They are nearly 100% effective, only very weakly reactogenic and they undoubtedly belong among the most perfect vaccines ever produced. The darker side of the anti-HPV vaccines is their high price, the fact that the highest benefits they bring will only become evident in 20 or 30 years, and that they do not afford protection against all oncogenic HPVs. It is therefore imperative that organized cytological screening be continued: it is destined to remain the main instrument of CaCer prevention for several decades. With all probability also other types of vaccine are under development, viz. VLP-based vaccines, whose range of applicability will be wider than that of the present preventive vaccines, as well as vaccines that will, hopefully, be able to inhibit already progressing infection or will be utilizable in CaCer immunotherapy.
- MeSH
- Alphapapillomavirus fyziologie MeSH
- dítě MeSH
- dospělí MeSH
- hromadná vakcinace MeSH
- infekce papilomavirem imunologie klasifikace prevence a kontrola MeSH
- lidé MeSH
- mladiství MeSH
- nádory děložního čípku prevence a kontrola virologie MeSH
- vakcíny proti papilomavirům imunologie MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
The E7 oncoprotein from Human papillomavirus type 16 (HPV16) is an attractive candidate for anti-cancer therapeutical vaccine development. In this study, we engineered different fusions of mutagenized coding sequence of E7 oncoprotein (E7ggg) with coat protein of Potato virus X (PVX CP) both on 5'- and 3'-terminus of PVX CP and evaluated the influence of the length of linker (no linker, 4, 15aa) connecting PVX CP and E7ggg on their production. At first the expression in Escherichia coli was conducted to assess the characteristics of the recombinant protein prior to be further produced in plants, that is, resultant proteins were used for screening of their immunological reactivity with antibodies against PVX CP and E7. Fusion proteins successfully expressed in bacteria and plants were partially purified and their reactivity and ability to form virus-like particles were evaluated with anti-E7 antibodies.
- MeSH
- 3' přiléhající oblast DNA MeSH
- 5' přiléhající oblast DNA MeSH
- Agrobacterium tumefaciens MeSH
- Escherichia coli MeSH
- exprese genu MeSH
- infekce papilomavirem imunologie virologie MeSH
- klonování DNA MeSH
- lidé MeSH
- lidský papilomavirus 16 genetika imunologie metabolismus MeSH
- nádory děložního čípku imunologie virologie MeSH
- Papillomavirus E7 - proteiny genetika imunologie metabolismus MeSH
- Potexvirus genetika imunologie metabolismus MeSH
- proteinové inženýrství metody MeSH
- protilátky imunologie MeSH
- rekombinantní fúzní proteiny genetika imunologie metabolismus MeSH
- tabák MeSH
- vakcíny proti papilomavirům chemie genetika MeSH
- virové plášťové proteiny genetika imunologie metabolismus MeSH
- VLP vakcíny chemie genetika MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Chřipka představuje jednu ze skupin infekcí, které způsobují významnou nemocnost i úmrtnost a zůstává vážným respiračním onemocněním. Nepředvídatelná variabilita chřipkového viru typu A způsobující každoroční epidemie je hlavním důvodem snahy dalšího vývoje protichřipkové vakcíny (univerzální chřipková vakcína, virus-like particles, proteinové/peptidové vakcíny, DNA vakcína). Každoroční protichřipková vakcinace některou registrovanou inaktivovanou vakcínou hraje v ČR klíčovou roli v prevenci této infekce.
Influenza is one of the groups of infections, which cause substantial morbidity and mortality and remains a serious respiratory disease. The unpredictable variability of influenza A viruses, which cause annual epidemics, is the main reason for developing new trends in influenza vaccine production (universal influenza vaccine, virus-like particles, recombinant protein and/or peptide vaccines, DNA vaccine) Annual vaccination by some type of authorised inactivated vaccine represents a basic tool in specific influenza prevention in the Czech Republic.
- Klíčová slova
- chřipkový virus, očkování proti chřipce, historie očkování proti chřipce, nové trendy v přípravě protichřipkové vakcíny,
- MeSH
- Alphainfluenzavirus izolace a purifikace klasifikace patogenita MeSH
- Betainfluenzavirus izolace a purifikace klasifikace patogenita MeSH
- chřipka lidská dějiny prevence a kontrola MeSH
- epidemie dějiny ekonomika prevence a kontrola MeSH
- inaktivované vakcíny aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- Influenzavirus C izolace a purifikace patogenita MeSH
- lidé MeSH
- pandemie dějiny ekonomika prevence a kontrola MeSH
- statistika jako téma MeSH
- Světová zdravotnická organizace MeSH
- vakcinace dějiny metody trendy MeSH
- vakcíny proti chřipce dějiny klasifikace terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
